The influence of benzbromarone and its combination with hydrochlorothiazide on renal excretion of uric acid and electrolytes.
The results of a study investigating the effect of single oral administration of B (benzbromarone), and a combination of B + H (hydrochlorothiazide), in 10 healthy volunteers suggest the following conclusions: 1) In agreement with literary data, B at a dose of 100 mg has a significant hypouricemic effect with a 39% decrease after 6 h, and a 53% decrease after 24 h. 2) B and B + H significantly enhance renal clearance and fractional excretion of uric acid but there was no demonstrable significant inverse relation between these parameters and the plasma level of uric acid. 3) B affects PUA (plasma concentration of uric acid) also by some extrarenal action which is not related to the pre-existing alteration of uric acid metabolism. 4) Simultaneous single administration of B + H does not reduce the effect of B on renal excretion and on the plasma level of uric acid. 5) A single dose of B causes a slight but significant decrease in fractional potassium excretion without any demonstrable effect on fractional excretion of sodium and that of all osmotically active substances.
Malý
J
J
Institute for Clinical and Experimental Medicine, Prague, Czechoslovakia.
Schück
O
O
D000284:Administration, Oral; D000328:Adult; D001553:Benzbromarone / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008657:Metabolic Clearance Rate; D011188:Potassium / Q000652:urine; D012964:Sodium / Q000652:urine; D013997:Time Factors; D014527:Uric Acid / Q000097:blood / Q000652:urine*
D006852:Hydrochlorothiazide; D014527:Uric Acid; D001553:Benzbromarone; D012964:Sodium; D011188:Potassium